Stephen Hahn, MD

“We live in a time of extraordinary scientific achievement, especially in oncology, with unprecedented opportunities to help make the lives of American patients and consumers healthier and safer.”

Stephen Hahn is the CEO at Harbinger Health and CEO-Partner at Flagship Pioneering. He previously served as the Commissioner of Food and Drugs at the U.S. Food and Drug Administration (FDA) between 2019 and 2021.

A radiation oncologist, he formerly served as Chief Medical Executive of the MD Anderson Cancer Center, where he oversaw one of the largest clinical trial groups in the country, and Professor and Chair of Radiation oncology at the University of Pennsylvania.

Trained in both medical oncology and radiation oncology, Hahn specializes in treating lung cancer and sarcoma. He has authored more than 220 peer-reviewed publications on his research, particularly the molecular causes of the tumor microenvironment and the evaluation of proton therapy as a means of improving the effectiveness of radiation therapy. His experience in medical product development and clinical trials spans drugs, biologics, medical devices, and diagnostics.

Hahn is a member of the American Association for Cancer Research, the American Society of Clinical Oncology, and the American Society for Radiation Oncology, of which he serves on the Board of Directors.

He obtained his B.A. in biology from Rice University and his M.D. from Temple University. He completed his residency at the University of California, San Francisco, before eventually becoming chief resident and a fellow at the National Institutes of Health (NIH). He earned the rank of Commander in the U.S. Public Health Service Commissioned Corps while at the NIH’s National Cancer Institute.